AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29131002 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (VT) of 6 mL/kg and moderate positive end-expiratory pressure (PEEP) of 8 cm H2O
Number of subjects: 44
Study 29131002 — intervention group
Group type: COMPARATOR
Intervention: High tidal volume (VT) of 10 mL/kg and zero end-expiratory pressure (ZEEP)
Number of subjects: 44
Study 26081329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol (500 mg/day intravenously for 14 days, then 500 mg twice a day orally for 60 days)
Number of subjects: 45
Study 26081329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mexidol)
Number of subjects: 45
Study 23652373 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate‐to‐vigorous aerobic exercise five times a week for approximately 16 weeks
Number of subjects: 391
Study 23652373 — intervention group
Group type: COMPARATOR
Intervention: Usual‐lifestyle sedentary control group
Number of subjects: 391
Study 21131165 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (PEI)
Number of subjects: 140
Study 21131165 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 19708896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene promotion intervention based on germ awareness
Number of subjects: 300
Study 19708896 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 300
Study 17361495 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxyzine 25 mg/d
Number of subjects: 50
Study 17361495 — intervention group
Group type: COMPARATOR
Intervention: doxepin 10 mg/d
Number of subjects: 50
Study 15281538 — intervention group
Group type: COMPARATOR
Intervention: loss‐of‐resistance with air
Number of subjects: 547
Study 15281538 — intervention group
Group type: EXPERIMENTAL
Intervention: loss‐of‐resistance with lidocaine
Number of subjects: 547
Study 15281538 — intervention group
Group type: EXPERIMENTAL
Intervention: loss‐of‐resistance with both air and lidocaine
Number of subjects: 547
Study 10828232 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 69
Study 9110743 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven therapeutic nursing interventions
Number of subjects: 50
Study 9110743 — intervention group
Group type: COMPARATOR
Intervention: Decisional control (control group)
Number of subjects: 50
Study 7903008 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG)
Number of subjects: 257
Study 7903008 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 257
Study 7903008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 2938615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azelaic acid
Number of subjects: 45
Study 2938615 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline
Number of subjects: 45
Study 31144674 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily
Number of subjects: 27395
Study 31144674 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 27395
Study 28678944 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP chewing gum
Number of subjects: 8
Study 28678944 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sugar free chewing gum
Number of subjects: 8
Study 28678944 — intervention group
Group type: COMPARATOR
Intervention: No chewing gum (control)
Number of subjects: 8
Study 25997770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention designed to prevent risk‐taking behaviors
Number of subjects: 172
Study 25997770 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 172
Study 23762355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping massage
Number of subjects: 61
Study 23762355 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 61
Study 20886278 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer‐assisted self‐interviewing (ACASI)
Number of subjects: 849
Study 20886278 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interview (FTFI)
Number of subjects: 849
Study 20886278 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 849
Study 20886278 — intervention group
Group type: COMPARATOR
Intervention: FTFI
Number of subjects: 849
Study 18647810 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily im P administration
Number of subjects: 29
Study 18647810 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg daily im P administration
Number of subjects: 29
Study 18647810 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural cycles)
Number of subjects: 29
Study 16244481 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (average dose 4.71 mg)
Number of subjects: 58
Study 16244481 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (average dose 1.75 mg)
Number of subjects: 58
Study 16244481 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine and Haloperidol
Number of subjects: 58
Study 12917230 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 3
Study 12917230 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg isoniazid
Number of subjects: 3
Study 12917230 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 3
Study 10535609 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus IL-2
Number of subjects: 21
Study 10535609 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 21
Study 8557903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 19394
Study 8557903 — intervention group
Group type: COMPARATOR
Intervention: Open control (no lisinopril)
Number of subjects: 19394
Study 8557903 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 19394
Study 8557903 — intervention group
Group type: COMPARATOR
Intervention: Open control (no glyceryl trinitrate)
Number of subjects: 19394
Study 1801054 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin 200 mg at night
Number of subjects: 88
Study 1801054 — intervention group
Group type: COMPARATOR
Intervention: macrocrystalline nitrofurantoin 100 mg at night
Number of subjects: 88
Study 6225686 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 15
Study 31609296 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt intake (3900 mg·d)
Number of subjects: 19
Study 31609296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 19
Study 31609296 — intervention group
Group type: COMPARATOR
Intervention: Sham trial (60 min of seated rest)
Number of subjects: 19
Study 30707881 — intervention group
Group type: EXPERIMENTAL
Intervention: Active abdominal compression‐decompression cardiopulmonary resuscitation (AACD‐CPR), n = 24
Number of subjects: 45
Study 30707881 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary resuscitation (CPR) with unarmed abdominal compression, n = 21
Number of subjects: 45
Study 30707881 — intervention group
Group type: EXPERIMENTAL
Intervention: AACD‐CPR
Number of subjects: 45
Study 28968543 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 2275
Study 27083930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) 400 mg
Number of subjects: 84
Study 27083930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (LCZ696) 1200 mg
Number of subjects: 84
Study 27083930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27083930 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 84
Study 25122979 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush (Oral-B Triumph with SmartGuide and FlossAction brush head)
Number of subjects: 130
Study 25122979 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush (Sonicare FlexCare Platinum)
Number of subjects: 130
Study 21916999 — intervention group
Group type: EXPERIMENTAL
Intervention: TCH (1.35% taurolidine, 4% citrate and 500 U/ml heparin)
Number of subjects: 106
Study 21916999 — intervention group
Group type: COMPARATOR
Intervention: TC (1.35% taurolidine in 4% citrate)
Number of subjects: 106
Study 21916999 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 106
Study 20465525 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1139
Study 20465525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 20465525 — intervention group
Group type: COMPARATOR
Intervention: Routine-care
Number of subjects: 1139
Study 17345042 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg, bi.d.)
Number of subjects: 314
Study 17345042 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (once-daily dosing)
Number of subjects: 314
Study 17345042 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (once-daily dosing during titration and short-term maintenance therapy)
Number of subjects: 314
Study 16280695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 997
Study 16280695 — intervention group
Group type: COMPARATOR
Intervention: Optimized background regimen alone (Control)
Number of subjects: 997
Study 12032018 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 mL)
Number of subjects: 250
Study 12032018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 250
Study 12032018 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (30 mg)
Number of subjects: 250
Study 12032018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 250
Study 12032018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (100 microg)
Number of subjects: 250
Study 9477390 — intervention group
Group type: COMPARATOR
Intervention: Low carotenoid diet with 0.5 mg/day of Beta-carotene (Group C)
Number of subjects: 9
Study 9477390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carotenoid diet without supplementation (Group P)
Number of subjects: 9
Study 9477390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 0.5 mg/day of Beta-carotene (Group C and Group P) during period 2
Number of subjects: 9
Study 7879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Redox tolerance test before percutaneous transhepatic biliary drainage
Number of subjects: 29
Study 7879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Redox tolerance test after percutaneous transhepatic biliary drainage
Number of subjects: 29
Study 7879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Redox tolerance test before drainage with RTI < 0.5
Number of subjects: 29
Study 7879830 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality in patients with initial RTI < 0.5
Number of subjects: 29
Study 1994656 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2377
Study 6558739 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental method of counseling
Number of subjects: 122
Study 6558739 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of counseling
Number of subjects: 122
Study 6558739 — intervention group
Group type: COMPARATOR
Intervention: Negative pregnancy test counseling
Number of subjects: 122
Study 6558739 — intervention group
Group type: COMPARATOR
Intervention: Routine medical visit counseling
Number of subjects: 122
Study 29707867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy followed by narrow band ultraviolet‐B (NB‐UVB) phototherapy
Number of subjects: 32
Study 29707867 — intervention group
Group type: COMPARATOR
Intervention: Narrow band ultraviolet‐B (NB‐UVB) alone
Number of subjects: 32
Study 30275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2/day x7 days
Number of subjects: 485
Study 30275526 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 485
Study 26502869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UDCA 4×250 mg daily (Group 1)
Number of subjects: 120
Study 26502869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous SAMe 1000 mg daily (Group 2)
Number of subjects: 120
Study 26502869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UDCA and SAMe (Group 3)
Number of subjects: 120
Study 24060628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy focused on eating disorder features
Number of subjects: 80
Study 24060628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy focused on mood intolerance, clinical perfectionism, core low self-esteem or interpersonal difficulties
Number of subjects: 80
Study 24060628 — intervention group
Group type: COMPARATOR
Intervention: Both programmes
Number of subjects: 80
Study 21883279 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-grass-pollen daily tablet sublingually for 4 months
Number of subjects: 89
Study 21883279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19958547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits (PHV) intervention, 4 times over a 12 month follow-up period.
Number of subjects: 110
Study 19958547 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention of mailed printed materials (comparison group).
Number of subjects: 110
Study 16487162 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) between a TMS pulse and an electrical stimulus to the median nerve
Number of subjects: 6
Study 16487162 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor practice of rapid thumb abduction
Number of subjects: 6
Study 16487162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory input produced by semicontinuous muscle vibration
Number of subjects: 6
Study 15489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured by CSA activity monitors)
Number of subjects: 210
Study 15489468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean METS per minute
Number of subjects: 210
Study 10758689 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 79
Study 10758689 — intervention group
Group type: EXPERIMENTAL
Intervention: EBA
Number of subjects: 79
Study 10758689 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 79
Study 8828025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg/day for 2 weeks
Number of subjects: 116
Study 8828025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8828025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg/day for 4 months
Number of subjects: 116
Study 8828025 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 10 mg/day for 4 months
Number of subjects: 116
Study 1593044 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent
Number of subjects: 223
Study 1593044 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 223
Study 1593044 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser balloon angioplasty
Number of subjects: 223
Study 1593044 — intervention group
Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 223
Study 6741445 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml Gelusil orally (Group I, n = 17)
Number of subjects: 33
Study 6741445 — intervention group
Group type: COMPARATOR
Intervention: 30 ml of 0.3 mol/l sodium citrate (Group II, n = 16)
Number of subjects: 33
Study 31350167 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic CVT patients
Number of subjects: 812
Study 29396246 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus mycophenolate
Number of subjects: 164
Study 29396246 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone alone
Number of subjects: 164
Study 25647351 — intervention group
Group type: EXPERIMENTAL
Intervention: PM cues with category discrepancy (Body Parts)
Number of subjects: 0
Study 25647351 — intervention group
Group type: COMPARATOR
Intervention: PM cues with category congruence
Number of subjects: 0
Study 24617270 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of gratitude intervention
Number of subjects: 0
Study 24617270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acts of kindness intervention
Number of subjects: 0
Study 24617270 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 22398106 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (up to three face-to-face and ten telephone contacts over 8 months)
Number of subjects: 361
Study 22398106 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 361
Study 22398106 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 361
Study 20517084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue and quilting
Number of subjects: 35
Study 20517084 — intervention group
Group type: COMPARATOR
Intervention: Quilting alone
Number of subjects: 35
Study 18024309 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 and folic acid treatment in addition to aspirin and IVIG
Number of subjects: 76
Study 18024309 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and IVIG alone
Number of subjects: 76
Study 15655011 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 1500 mg and Methylene Blue (MB) 780 mg over 3 days
Number of subjects: 74
Study 11863236 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental information group
Number of subjects: 60
Study 11863236 — intervention group
Group type: COMPARATOR
Intervention: Contact-control condition
Number of subjects: 60
Study 10448728 — intervention group
Group type: EXPERIMENTAL
Intervention: No implant
Number of subjects: 70
Study 10448728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized dura implant
Number of subjects: 70
Study 10448728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethisorb implant
Number of subjects: 70
Study 10448728 — intervention group
Group type: EXPERIMENTAL
Intervention: e-PTFE implant
Number of subjects: 70
Study 10448728 — intervention group
Group type: COMPARATOR
Intervention: Implants (combined)
Number of subjects: 70
Study 10448728 — intervention group
Group type: COMPARATOR
Intervention: Overall (no implant vs implants)
Number of subjects: 70
Study 10448728 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound complications
Number of subjects: 70
Study 8574160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) during consolidation chemotherapy
Number of subjects: 56
Study 8574160 — intervention group
Group type: COMPARATOR
Intervention: Placebo during consolidation chemotherapy
Number of subjects: 56
Study 8574160 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) during induction chemotherapy
Number of subjects: 56
Study 8574160 — intervention group
Group type: COMPARATOR
Intervention: Placebo during induction chemotherapy
Number of subjects: 56
Study 2086411 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB contact lenses
Number of subjects: 50
Study 2086411 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA contact lenses
Number of subjects: 50
Study 2086411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contact lenses)
Number of subjects: 50
Study 264991 — intervention group
Group type: EXPERIMENTAL
Intervention: Branch A of the randomised DAL study series (1/71)
Number of subjects: 78
Study 264991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified initial therapy (11/73)
Number of subjects: 78
Study 264991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosin-arabinoside orally
Number of subjects: 78
Study 31364911 — intervention group
Group type: EXPERIMENTAL
Intervention: Wixela Inhub (100/50 μg FP/S)
Number of subjects: 66
Study 31364911 — intervention group
Group type: EXPERIMENTAL
Intervention: Wixela Inhub (250/50 μg FP/S)
Number of subjects: 66
Study 31364911 — intervention group
Group type: EXPERIMENTAL
Intervention: Wixela Inhub (500/50 μg FP/S)
Number of subjects: 66
Study 30674347 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Home (CP@home) program intervention
Number of subjects: 261
Study 30674347 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 261
Study 28695641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 87
Study 28695641 — intervention group
Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (CRH)
Number of subjects: 87
Study 24888575 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIM (free-mixed aspart and detemir insulin)
Number of subjects: 82
Study 24888575 — intervention group
Group type: COMPARATOR
Intervention: ANIM (premixed fixed-ratio aspart and NPH insulin)
Number of subjects: 82
Study 23624756 — intervention group
Group type: COMPARATOR
Intervention: ZT-1 (0.5 mg, po)
Number of subjects: 58
Study 23624756 — intervention group
Group type: COMPARATOR
Intervention: ZT-1 (0.75 mg, po)
Number of subjects: 58
Study 23624756 — intervention group
Group type: COMPARATOR
Intervention: ZT-1 (0.75 mg/d, po) for 8 consecutive days
Number of subjects: 58
Study 23624756 — intervention group
Group type: COMPARATOR
Intervention: ZT-1 (0.5, 0.75, 1, 1.25 or 1.5 mg, po)
Number of subjects: 58
Study 21306949 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional therapy with therapeutic pillow
Number of subjects: 18
Study 21306949 — intervention group
Group type: COMPARATOR
Intervention: Control night with hospital pillow and ad lib positioning
Number of subjects: 18
Study 19207633 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSLE (a systems and mentalization focused whole school intervention)
Number of subjects: 1345
Study 19207633 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSLE
Number of subjects: 1345
Study 19207633 — intervention group
Group type: COMPARATOR
Intervention: SPC (School Psychiatric Consultation)
Number of subjects: 1345
Study 19207633 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment‐as‐usual)
Number of subjects: 1345
Study 16477425 — intervention group
Group type: EXPERIMENTAL
Intervention: 12/14F coaxial ureteral dilator/sheath and a 7.5F flexible ureteroscope (group A; 48 patients)
Number of subjects: 98